Kamisha L. Johnson-Davis
No Rating Available
(Learn About Our Rating System)

Kamisha L. Johnson-Davis, PhD, Executive MBA

Languages spoken: English

  • Dr. Johnson-Davis is a Professor (Clinical) at the University of Utah in the Department of Pathology and Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside, a Ph.D. in Pharmacology, and an Executive MBA from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology, and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board-certified in Clinical Chemistry and Toxicological Chemistry. She is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the Association for Diagnostics & Laboratory Medicine.

    Specialties

    • Clinical Chemistry
    • Toxicology, Clinical

    Board Certification

    American Board of Clinical Chemistry (Sub: Toxicological Chemistry)
    American Board of Clinical Chemistry (Sub: Clinical Chemistry)

  • Dr. Johnson-Davis is a Professor (Clinical) at the University of Utah in the Department of Pathology and Medical Director for Clinical Toxicology at ARUP Laboratories. She received her B.S. degree in Biochemistry from the University of California, Riverside, a Ph.D. in Pharmacology, and an Executive MBA from the University of Utah. She was a postdoctoral research associate at the Center for Human Toxicology, and she completed a postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology. Dr. Johnson-Davis is board-certified in Clinical Chemistry and Toxicological Chemistry. She is a Diplomate of the American Board of Clinical Chemistry and a Fellow of the Association for Diagnostics & Laboratory Medicine.

    Board Certification and Academic Information

    Academic Departments Pathology -Professor (Clinical)
    Board Certification
    American Board of Clinical Chemistry (Sub: Toxicological Chemistry)
    American Board of Clinical Chemistry (Sub: Clinical Chemistry)

    Education history

    Undergraduate Biochemistry - University of California, Riverside, Department of Biochemistry B.S.
    Doctoral Training Pharmacology - University of Utah, Department of Pharmacology &Toxicology Ph.D.
    Postdoctoral Fellowship Human Toxicology - University of Utah, Center for Human Toxicology, Research Associate Postdoctoral Fellow
    Postdoctoral Fellowship Clinical Chemistry Fellowship program, Certificate #102 - University of Utah, Department of Pathology Postdoctoral Training
    Professional Other Master of Business Administration - University of Utah EMBA

    Selected Publications

    Journal Article

    1. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG (2015). A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol, 143(2), 234-40. (Read full publication)
    2. Wiencek JR, Gehrie EA, Keiser AM, Szklarski PC, Johnson-Davis KL, Booth G (2019). Detection of Nicotine and Nicotine Metabolites in Units of Banked Blood. American journal of clinical pathology, 151(5), 516-521. (Read full publication)
    3. Johnson-Davis KL, Fernelius C, Eliason NB, Wilson A, Beddhu S, Roberts W (2011). Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. Annals of clinical and laboratory science, 41(4), 331-9. (Read full publication)
    4. Lin CN, Juenke JM, Johnson-Davis K (2014). Method validation of a tricyclic antidepressant drug panel in urine by UPLC-MS/MS. Annals of clinical and laboratory science, 44(4), 431-6. (Read full publication)
    5. Petrides AK, Moskowitz J, Johnson-Davis KL, Jannetto PJ, Langman LJ, Clarke W, Marzinke M (2014). The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clinical biochemistry, 47(15), 73-9. (Read full publication)
    6. Johnson-Davis KL, Farnsworth C, Law C, Parker (2020). Method validation for a multi-element panel in serum by inductively coupled plasma mass spectrometry (ICP-MS). Clinical biochemistry, 82, 90-98. (Read full publication)
    7. Juenke JM, Miller KA, Ford MA, McMillin GA, Johnson-Davis K (2011). A comparison of two FDA approved lamotrigine immunoassays with ultra-high performance liquid chromatography tandem mass spectrometry. Clinica chimica acta; international journal of clinical chemistry, 412(19-20), 1879-82. (Read full publication)
    8. Johnson-Davis KL, Moore SJ, Owen WE, Cutler JM, Frank E (2009). A rapid HPLC method used to establish pediatric reference intervals for vitamins A and E. Clinica chimica acta; international journal of clinical chemistry, 405(1-2), 35-8. (Read full publication)
    9. Rockwood AL, Johnson-Davis K (2011). Mass spectrometry for clinical toxicology: therapeutic drug management and trace element analysis. Clinics in laboratory medicine, 31(3), 407-28. (Read full publication)
    10. Johnson-Davis KL, Fleckenstein AE, Wilkins D (2003). The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. European journal of pharmacology, 482(1-3), 151-4. (Read full publication)
    11. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins D (2007). Persistence of tolerance to methamphetamine-induced monoamine deficits. European journal of pharmacology, 559(1), 46-54. (Read full publication)
    12. Johnson-Davis KL, Hanson GR, Keefe K (2002). Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. Journal of neurochemistry, 82(6), 1472-9. (Read full publication)
    13. Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein A (2005). Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity. The Journal of pharmacology and experimental therapeutics, 314(3), 1087-92. (Read full publication)
    14. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins D (2004). Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. The Journal of pharmacology and experimental therapeutics, 309(2), 578-86. (Read full publication)
    15. Johnson-Davis KL, Thompson CD, Clark CJ, McMillin GA, Lehman C (2012). Method comparison of the Ortho Vitros Fusion 5,1 chemistry analyzer and the Roche COBAS Integra 400 for urine drug screen testing in the emergency department. Journal of analytical toxicology, 36(5), 345-8. (Read full publication)
    16. Marin SJ, Sawyer JC, He X, Johnson-Davis K (2015). Comparison of drug detection by three quadrupole time-of-flight mass spectrometry platforms. Journal of analytical toxicology, 39(2), 89-95. (Read full publication)
    17. Snozek CLH, Corey RL, Buras MR, Johnson-Davis K (2019). False-Positive Serum Cocaine Screening Results in Patients Undergoing Evaluation for Renal Transplant. Journal of analytical toxicology, 43(7), 587-590. (Read full publication)
    18. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein A (2005). Bupropion increases striatal vesicular monoamine transport. Neuropharmacology, 49(6), 820-30. (Read full publication)
    19. Juenke JM, Brown PI, Johnson-Davis KL, McMillin G (2011). Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. Therapeutic drug monitoring, 33(2), 209-13. (Read full publication)
    20. Juenke JM, Miller KA, McMillin GA, Johnson-Davis K (2011). An automated method for supporting busulfan therapeutic drug monitoring. Therapeutic drug monitoring, 33(3), 315-20. (Read full publication)
    21. Juenke JM, Wienhoff KA, Anderson BL, McMillin GA, Johnson-Davis K (2011). Performance characteristics of the ARK diagnostics gabapentin immunoassay. Therapeutic drug monitoring, 33(4), 398-401. (Read full publication)
    22. Johnson-Davis KL, De S, Jimenez E, McMillin GA, De B (2011). Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method. Therapeutic drug monitoring, 33(4), 453-9. (Read full publication)
    23. McMillin GA, Johnson-Davis K, Dasgupta (2012). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood. Therapeutic drug monitoring, 34(2), 222-6. (Read full publication)
    24. Rule GS, Rockwood AL, Johnson-Davis K (2015). LC-MS/MS Method for Determination of Teriflunomide, Over a 40,000-Fold Dynamic Range Using Overlapping Calibrators. Therapeutic drug monitoring, 37(4), 472-8. (Read full publication)
    25. Schniedewind B, Niederlechner S, Galinkin JL, Johnson-Davis KL, Christians U, Meyer E (2015). Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study. Therapeutic drug monitoring, 37(3), 296-303. (Read full publication)
    26. Johnson-Davis KL, Doyle (2020). Therapeutic Drug Monitoring in Pregnant Patients. Therapeutic drug monitoring, 42(2), 172-180. (Read full publication)
    27. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan (2019). Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic drug monitoring, 41(3), 261-307. (Read full publication)
    28. McMillin GA, Johnson-Davis KL, Kelly BN, Scott B, Yang Y (2021). Impact of the Opioid Epidemic on Drug Testing. Therapeutic drug monitoring, 43(1), 14-24. (Read full publication)
    29. Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJAR, Oellerich M, Picard N, Salzmann L, Tönshoff B, van Schaik RHN, Vethe NT, Vinks AA, Wallemacq P, Åsberg A, Langman L (2021). Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring, 43(2), 150-200. (Read full publication)
    30. Johnson-Davis KL, Hanson GR, Keefe K (2003). Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats. Neurotoxicity research, 5(4), 273-81. (Read full publication)
    31. McMillin GA, Slawson MH, Marin SJ, Johnson-Davis K (2013). Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management. Journal of pain & palliative care pharmacotherapy, 27(4), 322-39. (Read full publication)
    32. Gruzdys V, Merrigan SD, Johnson-Davis K (2019). Feasibility of Immunosuppressant Drug Monitoring by a Microsampling Device. The journal of applied laboratory medicine, 4(2), 241-246. (Read full publication)
    33. Kroner GM, Johnson-Davis KL, Doyle K, McMillin G (2020). Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. The journal of applied laboratory medicine, 5(3), 569-574. (Read full publication)
    34. Merrigan SD, Johnson-Davis K (2019). A 6 Second Analytical Method for Quantitation of Tacrolimus in Whole Blood by Use of Laser Diode Thermal Desorption Tandem Mass Spectrometry. The journal of applied laboratory medicine, 3(6), 965-973. (Read full publication)
    35. Wu F, Melis R, McMillin GA, Johnson-Davis K (2019). Retrospective Data Analysis of the Influence of Age and Sex on TPMT Activity and Its Phenotype-Genotype Correlation. The journal of applied laboratory medicine, 3(5), 827-838. (Read full publication)
    36. Yang YK, Johnson-Davis KL, Kelly BN, McMillin G (2020). Demand for Interpretation of a Urine Drug Testing Panel Reflects the Changing Landscape of Clinical Needs; Opportunities for the Laboratory to Provide Added Clinical Value. The journal of applied laboratory medicine, 5(5), 858-868. (Read full publication)
    37. Kroner GM, Thomas RL, Johnson-Davis K (2021). Retrospective Analysis of Pediatric and Adult Populations Using an LC-MS/MS Method for Oxcarbazepine/Eslicarbazepine Metabolite. The journal of applied laboratory medicine, 6(3), 637-644. (Read full publication)
    38. Smith KA, Merrigan SD, Johnson-Davis K (2018). Selecting a Structural Analog as an Internal Standard for the Quantification of 6-Methylmercaptopurine by LC-MS/MS. The journal of applied laboratory medicine, 3(3), 384-396. (Read full publication)
    39. Johnson-Davis K (2018). Opiate & Benzodiazepine Confirmations: To Hydrolyze or Not to Hydrolyze is the Question. The journal of applied laboratory medicine, 2(4), 564-572. (Read full publication)
    40. Hunsaker JJH, La'ulu SL, LaGrave D, Murphy W, Reichman HA, Snow TM, McMillin GA, Johnson-Davis KL, Genzen J (2022). Tobacco and Cannabis Use During Pregnancy. American journal of clinical pathology, 157(1), 146-152. (Read full publication)
    41. Okoye NC, Greene DN, Johnson-Davis K (2021). Is the Confirmatory Test Always Right? Sometimes Immunoassays Know What They Are Talking About. The journal of applied laboratory medicine, (Read full publication)
    42. Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman L (2023). Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. Therapeutic drug monitoring, 45(2), 191-199. (Read full publication)
    43. Bajaj AO, Ly D, Johnson-Davis K (2022). Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. Journal of mass spectrometry and advances in the clinical lab, 24, 100-106. (Read full publication)
    44. Bajaj AO, Kushnir MM, Kish-Trier E, Law RN, Zuromski LM, Molinelli AR, McMillin GA, Johnson-Davis K (2022). LC-MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity. Frontiers in pharmacology, 13, 836812. (Read full publication)
    45. Pandya V, Wilker C, Johnson-Davis K (2023). Longitudinal trends in meconium drug detection in 46 US states between the years 2015 and 2020. Journal of analytical toxicology, 47(6), 495-503. (Read full publication)
    46. Okoye NC, Zuromski LM, Johnson-Davis K (2023). Trends in Blood Lead Levels Quantified by ICP-MS: A Reference Laboratory Retrospective Study. The journal of applied laboratory medicine, (Read full publication)
    47. Smith K, Johnson-Davis KL, Shahrokh (2023). A New Broad-Spectrum Drug Screen for 127 Analytes by LC-MS/MS. The journal of applied laboratory medicine, 8(2), 240-250. (Read full publication)
    48. Bajaj AO, Parker R, Farnsworth C, Law C, Johnson-Davis K (2022). Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). Journal of mass spectrometry and advances in the clinical lab, 27, 33-39. (Read full publication)
    49. Baryeh K, Zhou R, Brown E, McMillin GA, Krasowski MD, Johnson-Davis K (2024). Retrospective Data Analysis Reveals Unusual Metabolism Pattern of Ethanol in Pediatrics as Compared to Adult and Geriatric Populations. The journal of applied laboratory medicine, (Read full publication)
    50. McMillin GA, Morad AW, Boyd JM, Johnson-Davis KL, Metz TD, Smid MC, Krasowski M (2024). Biological Testing and Interpretation of Laboratory Results Associated with Detecting Newborns with Substance Exposure. Clinical chemistry, 70(7), 934-947. (Read full publication)
    51. Johnson-Davis KL, Thomas R (2024). Quantification of Oxcarbazepine Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods in molecular biology (Clifton, N.J.), 2737, 387-395. (Read full publication)
    52. Johnson-Davis KL, Ly (2024). Quantification of Olanzapine by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods in molecular biology (Clifton, N.J.), 2737, 347-357. (Read full publication)
    53. Clarke WA, Salyer B, Hussey C, Gardiner J, Johnson-Davis K, Milone M (2021). Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples. The journal of applied laboratory medicine, 6(6), 1541-1550. (Read full publication)
    54. Snozek CLH, Yee CI, Bryksin J, Dahal R, Gerson B, Gherasim C, Hauff KD, Heger N, Huestis MA, Johnson-Davis KL, Knezevic CE, Love SA, Melanson SEF, Noguez JH, Pikulski M, Roper S, Tyagi M, Warrington JS, Yang HS, Yang Y (2024). Assessing knowledge gaps and educational needs in urine drug test interpretation among health care professionals. American journal of clinical pathology, (Read full publication)
    55. Merrigan SD, Kish-Trier E, Seegmiller JC, Johnson-Davis K (2017). LC-MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clinical mass spectrometry (Del Mar, Calif.), 3, 41-48. (Read full publication)
    56. Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJAR, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB, Langman L (2024). Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring, (Read full publication)
    57. Mathewson NJ, Okoye NC, Nelson HA, Pandya V, Moore C, Johnson-Davis K (2025). Beyond the baseline: quantification of two phosphatidylethanol homologues in whole blood by LC-MS-MS and retrospective data analysis from a National Reference Laboratory. Journal of analytical toxicology, 49(3), 191-200. (Read full publication)
    58. Bithi N, Ricks D, Walker BS, Law C, Johnson-Davis K (2024). Method validation of an inductively coupled plasma mass spectrometry (ICP-MS) assay for the analysis of magnesium, copper and zinc in red blood cells. Journal of mass spectrometry and advances in the clinical lab, 34, 21-27. (Read full publication)
    59. Shaaban S, Walker BS, Ji Y, Johnson-Davis (2024). TPMT and NUDT15 genotyping, TPMT enzyme activity and metabolite determination for thiopurines therapy: a reference laboratory experience. Pharmacogenomics, 25(16-18), 679-688. (Read full publication)
    60. Bajaj AO,Parker R,Farnsworth C,Law C,Johnson-Davis K (2023). Method validation of multi-element panel in whole blood by inductively coupled plasma mass spectrometry (ICP-MS). Journal of mass spectrometry and advances in the clinical lab, 27, 33-39. (Read full publication)
    61. Bajaj AO,Ly D,Johnson-Davis K (2022). Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. Journal of mass spectrometry and advances in the clinical lab, 24, 100-106. (Read full publication)
    62. Bajaj AO,Kushnir MM,Kish-Trier E,Law RN,Zuromski LM,Molinelli AR,McMillin GA,Johnson-Davis K (2022). LC'MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity. Frontiers in pharmacology, 13, (Read full publication)
    63. Merrigan SD,Kish-Trier E,Seegmiller JC,Johnson-Davis K (2017). LC'MS/MS method for quantitation of mycophenolic acid, mycophenolic acid acyl-glucuronide, and 7-O-mycophenolic acid glucuronide in serum. Clinical mass spectrometry (Del Mar, Calif.), 3, 41-48. (Read full publication)
    64. McMillin GA,Johnson-Davis K,Dasgupta (2012). Analytical performance of a new liquid chromatography/tandem mass spectrometric method for determination of everolimus concentrations in whole blood (Therapeutic Drug Monitoring (2012) 34, (222-226)). Therapeutic drug monitoring, 34(4), 485. (Read full publication)
    65. Adegoke AO, Jackson AN, La'ulu SL, Anderson C, Rudolf JW, Boyd JM, Johnson-Davis K (2025). Immunalysis Tapentadol Assay Reformulation Resolves Tramadol Interference. Journal of analytical toxicology, (Read full publication)
    66. Shean RC, Johnson-Davis K (2025). Broad-Spectrum Drug Screening Positivity Rates in Pediatrics and Adults: The Reference Laboratory Perspective. Therapeutic drug monitoring, (Read full publication)
    67. Smith K, Genesi BT, Boyd JM, Johnson-Davis K (2025). Improvements, Challenges, and the Investigation of Two Unknowns in Arsenic Urine Speciation Analysis by HPLC-ICP-MS: From Development to Post-implementation. Therapeutic drug monitoring, (Read full publication)

    Review

    1. Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-Davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris (2022). Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury. Current issues in molecular biology, 44(3), 1294-1315. (Read full publication)
    2. Hubbard JA, Johnson-Davis K (2024). Racism in Drug Testing. Clinics in laboratory medicine, 44(4), 607-617. (Read full publication)

    Book Chapter

    1. Johnson-Davis K (2020). Cyanide toxicity'a case study. Toxicology Cases for the Clinical and Forensic Laboratory, 473-479. (Read full publication)
    2. McMillin GA,Johnson-Davis K (2019). Issues of interferences in therapeutic drug monitoring. Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction, Second Edition, 215-231. (Read full publication)
    3. Maharjan AS,Johnson-Davis K (2019). Issues of interferences with immunoassays used for screening of drugs of abuse in urine. Critical Issues in Alcohol and Drugs of Abuse Testing, 129-139. (Read full publication)
    4. Johnson-Davis KL,Dasgupta (2016). Special Issues in Therapeutic Drug Monitoring in Patients With Uremia, Liver Disease, and in Critically Ill Patients. Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics, 245-260. (Read full publication)
    5. Johnson-Davis K,Fleckenstein (2007). Methamphetamine. xPharm: The Comprehensive Pharmacology Reference, 1-7. (Read full publication)
    6. McMillin G,Johnson-Davis (2013). Issues of Interferences in Therapeutic Drug Monitoring. Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction, 195-211. (Read full publication)
    7. Johnson-Davis (2013). Enzymes. Clinical Chemistry: Principles, Techniques, and Correlations: Seventh Edition, 262-291. (Read full publication)
    8. Johnson-Davis KL,McMillin G (2016). Application of Liquid Chromatography Combined with Mass Spectrometry or Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants. Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring, 57-81. (Read full publication)

    Letter

    1. Juenke JM, McGraw JP, McMillin GA, Johnson-Davis K (2012). Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method. Clinica chimica acta; international journal of clinical chemistry, (413(3-4)), 529-31.
    2. Johnson-Davis KL,Thompson CD,Clark CJ,McMillin GA,Lehman C (2010). High amphetamine/methamphetamine concentrations in urine can cause error codes on the ortho vitros® fusion 5,1 FS automated chemistry analyzer. Journal of analytical toxicology, 34(9), 607-608. (Read full publication)
    3. McMillin GA,Johnson-Davis K (2011). In reply. Clinical chemistry, 57(4), 644-645. (Read full publication)

    Abstract

    1. Jackson AN, Wyness SP, La'ulu SL, Rudolf JW, Johnson-Davis K (2023). Jackson AN, Wyness SP, La'ulu SL, Rudolf JW, Johnson-Davis KL. Increased False-positives vs Increased Interference Flags: Using the AU 5800 to Compare Two Ethyl Glucuronide Assays. AACC Annual Scientific Meeting, Anaheim, CA. July 23-27,2023 .
    2. Bithi N, Ricks D, Zuromski L, Kish-Trier E, Johnson-Davis K (2022). Method validation of an inductively coupled plasma mass spectrometry (ICP-MS) assay for the analysis of magnesium, copper and zinc in RBCs. Association of Clinical Laboratorians and Physician Scientists (ACLPS) Annual Meeting, University of Washington, Seattle, WA. June 23-25, 2022.
    3. Smith KA, Johnson-Davis KL, Shahrokh (2022). Small footprint, big screen: developing a broad-spectrum drug screen for over 100 analytes in urine/serum utilizing the Agilent Ultivo LC-MS/MS. Mass Spectrometry & Advances in the Clinical Laboratory (MSACL), Monterey, CA. April 5-8, 2022.
    4. Bajaj AO, Kushnir MM, Kish-Trier E, Law RN, Zuromski LM, McMillin GA, Johnson-Davis K (2022). Quantification of thiopurine metabolites and correlation with TPMT phenotype. Mass Spectrometry & Advances in the Clinical Laboratory (MSACL), Monterey, CA. April 5-8, 2022.
    5. Pandya V, Wilker C, Johnson-Davis K (2021). Are amphetamines the new opiates? Evolving trends of drug positivity rates and concentrations in a mega cohort of neonatal meconium specimens. AACC Annual Scientific Meeting, Atlanta, Georgia, Sept.26-30, 2021.
    6. Bajaj AO, Kushnir MM, Kish-Trier E, McMillin GA, Johnson-Davis K (2021). Automated separation and washing of red blood cells (RBC) from whole blood samples. AACC Annual Scientific Meeting, Atlanta, Georgia, Sept.26-30, 2021.
    7. Bajaj AO, Kushnir MM, Kish-Trier E, McMillin GA, Johnson-Davis K (2021). Stability evaluation of thiopurine metabolites in whole blood, washed RBCs and sample extracts. AACC Annual Scientific Meeting, Atlanta, Georgia, Sept.26-30, 2021.
    8. Clarke WA, Slayer B, Hussey C, Gardiner J, Johnson-Davis K, Milone MC, Salamone S (2021). Multi-site evaluation of immunoassays for antipsychotic drug measurement in clinical samples. International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Rome, Italy. Sept. 19-22, 2021.

    Other

    1. Bajaj AO, Kushnir MM, Kish-Trier E, McMillin GA, Johnson-Davis K (2021). Automated separation and washing of red blood cells (RBCs) from whole blood. [ IP.com PCOM000264613D.].
    2. Johnson-Davis KL, Boyd JM, May S, Genesi (2024). Johnson-Davis KL, Boyd JM, May S, Genesi B (2024) Navigating Blood Lead Testing During a Collection Tube Shortage. Clinical and Forensic Toxicology News (Quarterly, The Association for Diagnostics & Laboratory Medicine (ADLM/Cp). Available: https://myadlm.org/science-and-research/clinical-and-forensic-toxicology-news/archives/2024/march-2024.
    3. Wiencek J, Johnson-Davis K, Kampfrath T, Nichols J, Pagaduan J, Schuler E, Wiley C (2025). Laboratory Medicine: Advancing Quality in Patient Care.